Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. by Guo, W et al.
UC Davis
UC Davis Previously Published Works
Title


















eScholarship.org Powered by the California Digital Library
University of California
OPEN
Targeting Btk/Etk of prostate cancer cells by a novel
dual inhibitor
W Guo1, R Liu*,1, G Bhardwaj1, JC Yang2, C Changou1, A-H Ma1, A Mazloom1, S Chintapalli1,3, K Xiao1, W Xiao1, P Kumaresan1,
E Sanchez1, C-T Yeh4, CP Evans2, R Patterson1,3, KS Lam1 and H-J Kung*,1,5
Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B
cells and has an important role in immune responses and B-cell malignancies. Etk has been shown previously to provide a
strong survival and metastasis signal in human prostate cancer cells, and to confer androgen independence and drug
resistance. While the role of Etk in prostate carcinogenesis is well established, the functions of Btk in prostate cancer have never
been investigated, likely due to the perception that Btk is a hematopoietic, but not epithelial, kinase. Herein, we found that Btk is
overexpressed in prostate cancer tissues and prostate cancer cells. The level of Btk in prostate cancer tissues correlates with
cancer grades. Knockdown of Btk expression selectively inhibits the growth of prostate cancer cells, but not that of the normal
prostate epithelial cells, which express very little Btk. Dual inhibition of Btk and Etk has an additive inhibitory effect on prostate
cancer cell growth. To explore Btk and Etk as targets for prostate cancer, we developed a small molecule dual inhibitor of Btk and
Etk, CTN06. Treatment of PC3 and other prostate cancer cells, but not immortalized prostate epithelial cells with CTN06 resulted
in effective cell killing, accompanied by the attenuation of Btk/Etk signals. The killing effect of CTN06 is more potent than that of
commonly used inhibitors against Src, Raf/VEGFR and EGFR. CTN06 induces apoptosis as well as autophagy in human prostate
cancer cells, and is a chemo-sensitizer for docetaxel (DTX), a standard of care for metastatic prostate cancer patients. CTN06
also impeded the migration of human prostate cancer cells based on a ‘wound healing’ assay. The anti-cancer effect of CTN06
was further validated in vivo in a PC3 xenograft mouse model.
Cell Death and Disease (2014) 5, e1409; doi:10.1038/cddis.2014.343; published online 4 September 2014
Prostate cancer is the most frequently diagnosed cancer and
the second leading cause of cancer deaths in men in the
United States.1 The risk and side effects associated with
current therapies, which range from impotence and incon-
tinence after surgery to recurrence of an androgen-indepen-
dent tumor after androgen ablation therapy, are severe.
Tyrosine kinase inhibitors (TKIs) are among the most
promising targeted therapies, most of which are directed
against receptor tyrosine kinases. The outcomes of clinical
trials based on TKIs as single agents have generally been
modest, probably due to redundancy in receptor binding and
signaling to intracellular mediators.2
The Tec family of tyrosine kinases is the second largest
family of cytoplasmic tyrosine kinases. It consists of six
members with tissue-specific expression patterns in normal
cells. Btk is the prototype of this family of tyrosine kinases.
Btk is reportedly expressed primarily in B cells, monocytes,
macrophages and neutrophils,3 as well as in B-cell malig-
nancies. In addition to being a critical effector for the B-cell
receptor,4 Btk engages B-cell Toll-like receptors (e.g., TLR2
and TLR4)5,6 and FAS.3 Btk is activated by SFK (src family
kinases) and Syk, and transmits signals to PI3K and PLC-
gamma, resulting in a calcium flux and the activation of NF-kB
and NFATc transcriptional factors.7,8 The role of Btk in the
immune response and hematopoietic malignancies has been
well studied. Deficiency of Btk in humans leads to X-linked
agammaglobulinemia (XLA).4 Btk has been reported as an
anti-apoptotic protein in neutrophils and macrophages. Btk-
deficient neutrophils have increased production of ROS and
stimulation-induced apoptosis.3 Knockdown of Btk in macro-
phages led to increased LPS and TNF-induced apoptosis.6
Btk also has an important role in arthritis, leukemia and
lymphoma. Several Btk inhibitors have been reported includ-
ing LFM-A13, a reversible Btk inhibitor through rational
design,9 and PCI32765, an irreversible Btk inhibitor. PCI-
32765 has shown encouraging effect in clinical studies for
treatment of chronic lymphocytic leukemia and in collagen-
induced arthritis mouse model.10–12 These inhibitors also
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exhibited potential in targeting multiple myeloma in the bone
marrowmicroenvironment.13 Although these inhibitors greatly
broadened the scope for potential Btk targeting in human
diseases, reactivity of irreversible inhibitor with other proteins
remains a concern. As a result, the development of a potent,
reversible Btk inhibitor is highly desirable.
As described above,most reported studies of Btk focused on
the hematopoietic system; however, the role of Btk in solid
tumors remains unknown. By contrast, Etk (also called BMX),
another member of Tec family, has been shown to be
expressed in epithelial and endothelial cells, and is involved
in the development or treatment resistance of several epithelial
malignancies.14–16 It is overexpressed in human prostate
cancer specimens, and provides strong survival functions in
prostate cancer cells.17,18 Overexpression of Etk induces
prostate intraepithelial neoplasia in mice,19 and knockout of
Etk in an endothelial lineage decreases tumor angiogenesis
and growth.20 We showed previously that Etk forms a complex
with Src and FAK, and that it is an effective activator of
STAT3.21,22 In prostate cancer cells, it is activated by EGFR
and erbB3,23 as well as IL-6 and neuropeptides, leading to
aberrant activation of androgen receptor.24 Etk sequesters p53
and confers survival and therapeutic resistance.25 In glioblas-
toma, Etk was found to be critical in maintaining the
self-renewal and tumorigenic potential of cancer stem cells
through Stat3 activation.26 Therefore, systemic inhibition of Etk
may offer a synergistic anti-tumor effect. As of yet, there is no
efficacious inhibitor for this kinase.
Herein, we report that Btk is also aberrantly expressed in
prostate cancer. Moreover, a novel Btk and Etk dual inhibitor,
CTN06, was identified. CTN06 induces autophagy and
apoptosis in prostate cancer cells, and inhibits prostate
cancer xenograft tumor growth in vivo. To our knowledge,
this is the first report of the role of Btk in solid tumors, and also
the first report of a novel Btk/Etk dual inhibitor with an
application as an anti-cancer agent.
Results
Btk is expressed at high levels in prostate cancer. Etk
has previously been reported to be overexpressed in
prostate cancer, and it promotes growth, survival and
angiogenesis of prostate cancer.19,27 Btk, the closest
member of Etk in the human kinome, was mainly reported
in hematopoietic cells and B-cell malignancies. The role of
Btk in solid cancers remains unknown. Using a tissue
microarray assay, we found that Btk is overexpressed
in prostate cancer tissues. Significantly, the expression level
Figure 1 BTK is expressed in prostate cancers and cell lines. (a) The expression level of Btk in prostate cancer tissue was examined using tissue microarray. (b) The array
contains 28 benign, 48 gleason 6 (CaP 6) and 46 gleason 8 (CaP 8) prostate cancer samples. (c) The antibody used was confirmed using cellblocks with PC3, PC3 with
depletion of Btk by SiBtk and RAMOS cells. (d) The expression level of Etk and Btk in prostate cancer cells was examined using western blot assay. (e) Btk levels in prostate
cancer cells were also measured using ELISA. (f) The antibody for tissue microarray was also confirmed using western blot with RAMOS cells and siBtk for PC3 cells, and with
Daudi cells as a positive control. (g) Btk levels were further confirmed using RT-PCR. Columns, mean; bars, standard deviation, n¼ 3
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of Btk correlates with the grade of prostate cancer (Figures
1a and b). The antibody used for tissue microarray was
confirmed using cell blocks with RAMOS cells as a positive
control (Figure 1c). In addition to the tissue microarray, the
expression level of Etk and Btk in prostate cancer cells
LNCaP, Du145, PC3 and immortalized normal prostate cell
RWPE1 was examined using western blots. Etk was found to
be high in PC3 cells, and Btk was found to be high in both
Du145 and PC3 cells, a similar expression pattern compared
with the tissue microarray (Figure 1d). Btk levels in RWPE1,
LNCaP, Du145 and PC3 cells were further measured using
ELISA (Figure 1e). The specificity of the Btk antibody used
was validated by the decreased Btk level, when Btk was
knocked down by siRNA targeting Btk in PC3 cells, as well as
in RAMOS cells which served as a positive control (Figure 1f).
The elevated mRNA levels of Etk and Btk in those cells were
also observed, using real-time RT-PCR, which indicates the
overexpression of Etk and Btk in prostate cancer cells is at
least in part at the transcriptional level (Figure 1g).
Simultaneous knockdown of Etk and Btk inhibits
prostate cancer cell growth. Etk knockdown has been
reported to slow down prostate cancer cell growth. A similar
result was observed in PC3 cells with Etk knockdown
(Figure 2a). To explore the role of Btk in prostate cancer
cell growth, the Btk level in PC3 prostate cancer cells was
knocked down using siRNA. Btk knockdown in PC3 cells
showed a similar inhibitory effect on prostate cancer cell
growth as compared with Etk knockdown. Simultaneous
knockdown of Etk and Btk resulted in a much greater
inhibitory effect on prostate cancer cell growth when
compared with Etk or Btk knockdown alone (Figure 2a). In
stark contrast, RWPE1, the immortalized normal prostate cell
line, is resistant to Etk and Btk knockdown (Figure 2b),
indicating an Etk/Btk ‘addiction’ of the prostate cancer cells.
The effect of Btk to prostate cancer cell growth was further
examined in PC3 cells and Du145 cells using SiBtk and LFM-
A13, a known Btk inhibitor. Both approaches inhibited
prostate cancer cell growth at a similar level, further
confirming an important role of Btk in prostate cancer cell
growth (Figure 2c).
CTN06 as a dual inhibitor against Btk and Etk tyrosine
kinases. Having identified a tumor-specific role of Btk and
Etk in prostate cancer, we attempted to develop inhibitors
targeting this family of kinases. Through screening a 9600-
diversity combinatorial solution phase small molecule library,
hit compounds with inhibitory activities against Etk were
discovered. Subsequent optimization led to the identification
of CTN06 (Figure 3a). To determine the substrate specificity
of this compound, purified Etk, Btk, Src and Mer were
incubated in a kinase reaction buffer with CTN06 (0–10 mM)
in the presence of 33P-labeled ATP and a peptide
(YIYGSFK), previously shown to be an excellent substrate
for both Btk and Src family kinases. The kinase activity was
measured using the thin-layer chromatography (TLC) tech-
nique. CTN06 was found to be an even more potent
Btk inhibitor with an IC50 of B50 nM compared with Etk
(IC50E200nM) (Figure 3b). Inhibition was observed in a
concentration-dependent manner. Src (IC50E5 mM) and Mer
(IC50410mM) were significantly more resistant to CTN06
inhibition (Figures 3b and c).
Figure 2 Both Btk/Etk (BMX) contribute to proliferation of prostate cancer cells. (a and b) The expression of Etk and Btk in PC3 and RWPE1 cells was knocked down using
the corresponding siRNA. The growth of the knockdown cells was measured using MTT assay. (c) The effect of Btk on prostate cancer cell growth was further confirmed using
siBtk and LFM-A13 (50 mM) in PC3 and Du145 cells. Columns, mean; bars, standard deviation, n¼ 3
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In addition to the Btk family tyrosine kinases, the inhibitory
activity of CTN06 against other tyrosine kinases, including Itk,
Lyn, Axl, Mer, EGFR and Abl, was investigated using the TLC
assay. CTN06 appears to have the strongest activity toward
Btk and Etk, followed by Itk, another member in the same
family. No significant inhibitory activity toward any other
kinases was observed (Figure 3d).
The inhibitor specificity is supported by the molecular
docking studies. CTN06 is found to bind to the pocket of the
ATP binding site with a binding energy of  11 kcal/mol
(Figures 3e and f). Previous studies have shown kinase
inhibitors that bind to this pocket.28,29 Further analysis through
molecular dynamics reveals that CTN06 interacts with the
‘gatekeeper’ residue T474. CTN06 also interacts with the side
Figure 3 CTN06 is a potent Etk and Btk dual inhibitor. (a) Chemical structure of CTN06. (b) The potency of CTN06 to Btk, Etk, Src and Mer was measured using TLC to
identify 33P-phosphorylated peptide substrate. Purified TKs (20 nM), CTN06 (0–10 mM) and the peptide substrate (YIYGSFK) were incubated with 33P-ATP in a kinase
reaction. The resulting product was analyzed on a TLC plate. (c) The intensity of the radioactive spot was measured using densitometer. (d) Summarization of the kinase
inhibition profile of CTN06. Columns, mean; bars, standard deviation, n¼ 3. Molecular docking of CTN06 to Btk. (e) Surface view of Btk docked to CTN06 after 20 ns of MD
relaxation. Brown: helix C (439–452); green: activation loop helix 1 (AH1) (541–546) and activation loop helix 2 (AH2) (548–553); yellow: DFG motif (538–540); blue: Thr474;
red: Cys480. (f) Cartoon representation showing predicted interactions of Btk with CTN06. Thr474, Leu408, Cys480 and Asp538 side chains are shown as sticks and colored
based on residue type (red: acidic, green: polar, yellow: non-polar). DFG motif is shown in red. Figures were generated using PyMol
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chains of C480, which is a residue unique to Btk when
compared with other kinases. Previous studies have shown
that only 8 kinases out of 491 that show T474 and C480
combination at these positions.28 Molecular dynamics studies
reveal that CTN06-Btk binding is stable. We analyzed the
molecular dynamics trajectories (Supplementary movie) and
plotted putative hydrogen bonding and hydrophobic interac-
tions between CTN06-Btk using LigPlotþ (Supplementary
Figure S2). CTN06 putatively forms multiple hydrophobic
interactions with side chains of the pocket. The R1 group
interacts with T474, as well as the DFG motif that is important
for kinase activity. R2 and the three-ring core interact with the
Glycine-rich loop region, as well as C480. Overall, computa-
tional studies show that CTN06 binds to Btk in a stable
manner, and the interactions with the back pocket, gate-
keeper threonine and the DFG motif lead to its kinase
inhibitory properties.
CTN06 preferentially inhibits the growth of malignant
prostate cells. To determine the effect of CTN06 on
proliferation, a panel of cancer cell lines including LNCaP,
Du145, PC3 and the immortalized normal prostate epithelial
cell line, RWPE1, were incubated with CTN06 and their
proliferation was measured using the MTT assay. CTN06
was very effective in inhibiting the growth of prostate cancer
cells (PC3, Du145 and LNCaP), while RWPE1 was much
more resistant to CTN06. The ability of CTN06 to inhibit Btk
activation, based on phospho-Btk (pBTK) expression in
those cells was confirmed using western blot (Figure 4a).
CTN06 induces autophagy in prostate cancer cells.
Previously, we showed that the Src inhibitor AZD0530
induces autophagy in prostate cancer cells, which contri-
butes to apoptosis resistance and diminishes the efficacy of
the Src inhibitor.30 To determine whether CTN06 can trigger
autophagy, PC3 cells stably transfected with GFP-LC3 were
treated with CTN06 and then examined under fluorescence
microscopy. After 2 and 24 h treatment with CTN06, these
cells yielded extensive, distinct ‘puncta’ autophagosome
morphology, whereas vehicle treatment did not. The ability
of CTN06 to induce autophagy in PC3 cells was further
confirmed by the conversion of endogenous LC3-I to the
lipidated LC3-II forms. Addition of chloroquine (CQ), an
autophagy blocker and lysosomal disruptor, resulted in
the accumulation of larger autophagosomes, suggesting
CTN06’s effect is on the induction of autophagosome
formation (Figure 4b).
CTN06 induces apoptosis in prostate cancer cells. To
determine whether the growth inhibition induced by CTN06
on prostate cells was due to apoptosis, flow-cytometric
analysis was carried out. Following treatment with CTN06 for
24 h, a dose-dependent accumulation of a ‘sub-G1’ fraction
was observed using propidium iodide (PI) staining. Data
based on Annexin-V reactivity also indicated a dose-
dependent increase in apoptosis of PC3 cells following
treatment with CTN06 (Figure 4c). The ‘sub-G1’ fraction only
measures dead cells with DNA content loss, which may
explain why it was less than the percentage of apoptotic cells
measured by Annexin-V.
CTN06 inhibits prostate cancer cell migration. Tec-family
tyrosine kinases have been shown to have an important role
in cellular movement and cancer metastasis. To explore the
ability of CTN06 to inhibit cell migration, ‘wound healing’ of
PC3 cells was measured following treatment with CTN06. As
shown in Supplementary Figure S3, ‘wound healing’ of PC3
cells was greatly inhibited by CTN06 after 16 h. These results
suggest that CTN06 has the ability not only to suppress
prostate cancer cell growth, but also to inhibit cell migration,
implicating CTN06 as an anti-metastasis agent.
CTN06 inhibits the phosphorylation of Btk, Etk and the
downstream signal PLCc2, Stat3, Akt in prostate cancer
cells. The inhibitory activity of CTN06 against phosphoryla-
tion of Etk and Btk in intact cells was examined by western
blot. Btk as well as Etk phosphorylation in PC3 cells were
significantly inhibited at 0.5 and 2 mM. The pPLCg2 inhibition
is likely to result from Btk inhibition. A selective target for Etk
is STAT3,31 whose phosphorylation is also inhibited by
CTN06, so is Akt, another important downstream effector of
Etk (Figure 5). Interestingly, Src phosphorylation was greatly
inhibited in cells following treatment with CTN06 compared
with kinase inhibition assay. This may be due to inhibition of
Etk, which has been shown to cross activate Src.21
CTN06 modulates cancer-related miRNAs. Many miRNAs
have been reported to have a role in carcinogenesis. To
explore whether CTN06 modulates miRNAs, 272 miRNA
levels in PC3 cells were examined using a microarray assay
following treatment with CTN06. Among them, 22 exhibited
alterations 42 folds, for most of which, there are no
established functions in oncogenesis (Supplementary Figure
S4a). A number of them, however, are known to possess
oncogenic and tumor suppressive properties. We found that
those miRNAs with tumor suppressive properties were
generally upregulated, and those with oncogenic properties
were downregulated following treatment with CTN06
(Supplementary Figure S4b).32–43 For instance, Mir-132,
which is upregulated 29.9 folds following treatment with
CTN06, has been reported to be downregulated by promoter
methylation in prostate cancer cells. On the other hand,
CTN06 downregulates Mir-421 ( 46.3 folds), which has been
reported to downregulate ATM, a pro-apoptotic protein.42
CTN06 downregulates oncogenic-related genes. To
further explore the mechanism of anti-cancer effect of
CTN06 in prostate cancer cells, cDNA microarray assay
was performed in PC3 cells following treatment with CTN06.
Among the 772 genes examined, 57 genes were down-
regulated4 2 folds. Interestingly, 25 of which are oncogenic-
related genes (Supplementary Figure S4c). Among those
genes, Met, which is downregulated 2.1 folds following
treatment with CTN06, has been reported to be constitutively
activated in PC3 cells, and inhibition of Met led to significant
inhibition of PC-3 cell proliferation, clonogenicity, migration
and invasion.44 MYCBP, which is downregulated 2.1 folds by
CTN06, is a positive regulator of Myc. Downregulation of
MYCBP by miR22 suppresses oncogenic Myc activity.45
CTN06 has higher potency to inhibit prostate cancer cell
growth compared with other kinase inhibitors. To further
Btk and Etk dual inhibitor in prostate cancer
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explore the potency of CTN06 to prostate cancer cells, growth
inhibitory activity of CTN06 to PC3 cells was compared with
other kinase inhibitors including saracatinib (AZD0530), sor-
afenib, AG1478, 3ATA and LMF-A13. At 2mM, CTN06 showed
the highest potency to inhibit PC3 cell growth followed by
sorafenib (Figure 6a). This result indicated that CTN06 is a
potent inhibitor of prostate cancer cell growth.
CTN06 as a chemo-sensitizer. Our initial studies indicated
that CTN06 has good cytotoxicity toward a panel of prostate
cancer cells. To examine whether a Btk and Etk dual inhibitor
works effectively as a chemo-sensitizer, PC3 cells were co-
treated with CTN06 (0.25 mM) and the autophagy inhibitor
CQ (10mM), or docetaxel (DTX) (2 ng/ml). Growth inhibition
was determined using an MTT assay after 72 h. Interestingly,
Figure 4 CTN06 induces autophagy as well as apoptosis in prostate cancer cells. (a) Growth inhibition of CTN06 to LNCaP, Du145, PC3 prostate cancer and normal
prostate (RWPE1) cells. Cells were seeded at 5000 cells/well in 96-well plate overnight and treated with CTN06 at the indicated concentrations. The cell viability was measured
using MTT assay after 72 h. Columns, mean; bars, standard deviation, n¼ 3. Inhibition of Btk by CTN06 (0.5mM) in those cells was measured using western blot. (b) Induction
of autophagy in PC3 cells by CTN06. PC3 cells were stably transfected with GFP-LC3 and were grown in 6-well plate to 50% confluence and treated with CTN06. Autophagy
was visualized by GFP-LC3 ‘puncta’ at 2 and 24 h and immunoblot of endogenous LC3 isoforms 24 h after treatment. (c) Induction of apoptosis of PC3 cells following treatment
with CTN06. PC3 cells were seeded at 106 cells/ml (2 ml) in a 6-well plate overnight and then treated with CTN06 at the indicated concentrations for 24 h. Apoptosis was
analyzed using PI staining as well as Annexin V-FITC apoptosis detection kit. Columns, mean; bars, standard deviation, n¼ 3. In all, 0.5 and 2 mM are significantly different
from 0mM (*Po0.05, one-way ANOVA with Tukey test for pairwise comparison)
Btk and Etk dual inhibitor in prostate cancer
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a synergistic effect of CTN06 was observed when prostate
cancer cells were co-treated with CQ. In the case of DTX
co-treatment, less of a synergistic effect was observed when
CTN06 and DTX were added to the cells at the same time,
while a striking synergistic effect was observed when cells
were treated with DTX for 24 h before treatment with CTN06
(Figure 6b). Annexin-V and PI staining further confirmed that
combination of CTN06 and CQ induced apoptosis
(Figure 6c). This suggests that CTN06 is a chemo-sensitizer,
and blocking of autophagy by CQ promotes CTN06-induced
cell death.
CTN06 inhibits PC3 xenograft tumor growth in vivo. Given
the in vitro activity of CTN06 against prostate cancer cells, it is
important to validate these results in vivo. PC3 cells were
injected subcutaneously to nude mice. The mice were treated
with vehicle (control) or CTN06 at 10mg/kg daily via IP
injection. As shown in Figures 7a and b, CTN06 decreased
PC3 xenograft tumor growth without significant toxicity.
Furthermore, Ki67 staining indicated that CTN06 inhibited
tumor growth activity and cleaved caspase 3 staining indicated
that it also induced apoptosis (Figure 7c). Western blot of LC3I
to LC3II conversion suggested autophagy induction in PC3
xenograft tumors by CTN06 (Figure 7d).
Discussion
Tyrosine kinases have become important targets for drug
development. Powerful combinatorial chemistry approaches
and high-throughput screening assays have led to successful
identification of many kinase inhibitors.46–48 Our previous
work indicated that Etk is complexed with Src and FAK, and
has an important role in apoptosis, angiogenesis and
metastasis of prostate cancer cells.22 Etk activation is a
compensatory response to androgen deprivation, implicating
its overexpression in castration-resistance transition.49 In
addition, Etk interacts with p53 and controls the apoptosis
pathway.25 Etk’s role in other solid tumors including bladder
cancer, hepatocellular carcinoma, nasopharyngeal carci-
noma and breast cancer is well established.14–16,50 Etk has
recently been implicated in the self-renewal and tumorigenic
potential of glioblastoma stem cells.26 Etk, highly expressed in
endothelial cells, has been shown to be a critical tyrosine
kinase for angiogenesis and tumor growth.18 All these findings
Figure 5 Inhibition of cell signaling in PC3 cells following treatment with CTN06.
Cells were grown in 100-mm plate to 50% confluence and treated with CTN06 at the
indicated concentrations. Cells were harvested after 12 h. pEtk, Etk, pBtk, Btk, pSrc,
Src, pPLCg2, PLCg2, pStat3, Stat3, pAkt, Akt, pERK and ERK levels were
measured using the corresponding antibodies by western blot. One of three similar
experiments depicted
Figure 6 CTN06 as a chemo-sensitizer. (a) Comparison of CTN06 with other
kinase inhibitors. PC3 cells were seeded at 5000 cells/well in 96-well plates
overnight and treated with CTN06 or the other kinase inhibitors including AZD0530,
sorafenib, AG1478, 3ATA and LMF-A13 at 2mM. The cell viability was measured
using MTT assay after 72 h. (b) Growth inhibition of CTN06 and in combination with
10mM chloroquine (CQ) or 2 ng/ml docetaxel (DTX) to PC3 human prostate cancer
cells. Cells were seeded at 5000 cells/well in 96-well plate overnight and pretreated
with the corresponding co-treatments for 1 h, then treated with 0.25 mM CTN06. The
cell viability was measured using MTT assay after 72 h. (c) The apoptotic effect of
CTN06 in combination with CQ to PC3 cells was further measured using Annexin-V
and PI staining and flow cytometry. Columns, mean; bars, standard deviation, n¼ 3
Btk and Etk dual inhibitor in prostate cancer
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point to Etk as an appropriate therapeutic target. Yet,
surprisingly little is known about Etk selective inhibitors. One
recent report showed that an EGFR inhibitor, CI-1033, inhibits
Etk at a sub-micromolar level via irreversible modification of a
conserved cysteine residue.51 In this study, we set forth to
identify a selective inhibitor for Etk.
Perhaps, the most striking observation of this study is the
discovery that not only Etk is involved in prostate carcino-
genesis, but also its close relativeBtk. Previously, Btkwasmainly
reported in B cells and B-cell malignancies. Btk inhibitors have
been developed for the benefit of treating hematopoietic
diseases. The role of Btk in solid tumors remains totally
unknown. Here, we report that Btk is aberrantly expressed in
prostate cancer tissues and cells. The Btk expression level
increases with the higher grade tumors, and in the prostate
cancer cell lines, it is expressed at a much higher level in
androgen-independent cell lines than androgen-sensitive
LNCaP cells or immortalized normal epithelial cells. Indeed,
both Btk and Etk have a distinct but overlapping role in
prostate cancer growth and survival. Knockdown of individual
kinases attenuates the growth of PC3 cells, but simultaneous
knockdown has greater effects. Thus, while we were screen-
ing for Etk inhibitors, we also look for those that inhibit both,
and were able to identify CTN06 that inhibits both Etk and Btk
and to a lesser extent, Itk. To our knowledge, this is the first
selective Btk/Etk dual inhibitor reported to date.
CTN06 belongs to a novel class of reversible kinase
inhibitors with a chemical structure distinct from other known
TKIs. This inhibitor is most potent in inhibiting Btk followed by
Etk. Compared with known Btk inhibitors, the inhibitory
potency of CTN06 against Btk is about 100-fold stronger than
LFM-A13 which is a reversible Btk inhibitor (Figure 3b). There
are few Etk inhibitors reported so far. CI-1033 is a potent
irreversible EGFR inhibitor with moderate Etk inhibition, but
clinical study reported that CI-1033 is associated with severe
toxicity.52 Therefore, a reversible Etk inhibitor such as CTN06
may have advantages and is probably less toxic. Treatment of
PC3 cells with CTN06 resulted in the decrease in phosphor-
ylation of Btk and Etk, as well as the downstream signals
PLCg2, Stat3 and Akt. Interestingly, Src phosphorylation was
greatly inhibited in cells following treatment with CTN06
compared with kinase inhibition assay. This is likely due to
inhibition of Etk, which has been shown to crossactivate Src.
21 Significantly, CTN06 has much less effect on the growth of
the immortalized normal prostate cell RWPE1, consistent with
the Btk/Etk knockdown experimental results (Figure 2). While
PC3 and DU145 have much higher expression level of Btk,
LNCaP expresses both Etk and Btk about the same level as
RWPE1; yet LNCaP appears to be more sensitive to CTN06
than RWPE1, suggesting that prostate cancer cells have
adapted to the Etk/Btk pathway for growth and survival, much
more so than normal prostate epithelial cells. This provides a
strong rationale for targeting Btk/Etk pathway in prostate
cancer cells. In addition, we and others previously reported
that Src inhibitors such as saracatinib (AZD0530) or dasatinib,
while effective in inhibiting metastasis, are generally not
inducers of apoptosis, which is in part due to their ability to
induce autophagy.30,53 By contrast, CTN-06 induces a high
level of apoptosis, despite its ability to induce autophagy. This
is likely due to the fact that Etk also interacts with and
inactivates p53. Overexpression of Etk in prostate cancer
cells is known to confer apoptosis resistance to androgen
deprivation and photodynamic therapy.17,49 Given the anti-
apoptotic role of Btk in B-cell malignancies, it is likely that
Figure 7 Inhibition of PC3 xenograft tumor growth by CTN06. 2 106 PC3 cells were injected subcutaneously to nude mice. The tumors were grown to the indicated size
and the mice were randomly divided into two groups (8 mice/group). The control group was treated with vehicle. The treatment group was treated with CTN06 at 10 mg/kg daily
via IP injection. (a and b) The tumor size and body weight were measured once a week. Marks, mean; bars, mean; n¼ 8 (*Po0.05, one-way ANOVA with Tukey test for
pairwise comparison). (c and d) The tumor samples were further analyzed for Ki67 and cleaved caspase 3 using immunohistochemistry and LC3I to LC3II conversion using
western blot
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inhibition of Btk also contributes to the induction of apoptosis
in prostate cancer cells. In addition, the effects of CTN06 on
miRNAs could in part account for its ability to induce apoptosis
in prostate cancer cells. This suggests that dual inhibitors of
Btk/Etk, which connects to Src pathway, may offer a more
effective alternative to Src inhibitors in terms of cell killing.
Indeed, we found CTN06 is a much more effective growth
inhibitor than AZD0530 (Figure 6a) as well as other currently
approved anti-cancer drugs.
The finding that autophagy inhibitor CQ further enhances
the apoptosis-inducing effect of CTN06 suggests that here,
like that in the case of other tyrosine kinase inhibitors,30
autophagy contributes partially to the survival of CTN06-
treated cells. Thus, autophagy inhibitor may be considered to
enhance the efficacy of this compound. CTN06 is also a
chemo-sensitizer and showed synergistic effect with DTX,
indicating its potential role in combination therapy for prostate
cancer. Interestingly, the sequence of its application is
important. DTX followed by CTN06 is more effective than
the reverse. This is understandable, as DTX action requires
the cell-cycle movement to G2/M phase, which may be
impeded if CTN06 was added first. Finally, consistent with
Etk’s role in cellular movement and as a co-activator of FAK,21
CTN06 was found to inhibit migration of prostate cancer cells.
We thus anticipate that CTN06 should also have the ability to
limit tumor metastasis. However, the genetic characters (e.g.,
AR and p53 status) of prostate cancer may influence their
responses to drug treatment. Further investigation is desired
to explore the effect of these factors to the response of
prostate cancer cells to CTN06.54
In summary, we found that Btk is aberrantly expressed in
prostate cancer, which together with Etk present suitable
targets for therapy. We have identified a Btk and Etk dual
inhibitor, CTN06, with good selectivity toward prostate cancer
cells. Further evaluation of its pharmacokinetic and pharma-
codynamic properties is underway. Btk and Etk dual inhibition
holds exceptional promise as a novel treatment strategy for
prostate cancer.
Materials and Methods
Reagents. Purified Etk, Btk, Itk, Mer, Yes, Lyn and Src kinases were obtained
from Millipore Inc (Dundee, UK). PI, N,N-diisopropylethylamine (DIEA), N,N-
dimethylformamide (DMF), ethanol, acetonitrile (ACN), N-Methyl-2-pyrrolidone
(NMP), 1-(3-aminopropyl)piperidine, trifluoroacetic acid (TFA), Pd/C, ammonium
formate, cyanogen bromide and dimethyl sulfoxide (DMSO) were purchased from
Sigma-Aldrich (Saint Louis, MO, USA). L-Leucine methyl ester hydrochloride and
4-(4-pyridinyl)benzoic acid were purchased from Chem-Impex International Inc
(Wood Dale, IL, USA). The Annexin V-FITC apoptosis detection kit was obtained
from Abcam (Cambridge, MA, USA). Reverse-phase high-performance liquid
chromatography (RP-HPLC) from the Waters Corporation (Milford, MA, USA) was
used for analysis and purification of CTN06.
Synthesis of CTN06. In brief, a solution of L-leucine methyl ester
hydrochloride (545.1 mg, 3.0 mmol) and DIEA (1.15 ml, 6.6 mmol) in DMF
(4.5 ml) was added dropwise under vigorous stirring to a solution of 1,5-difluoro-
2,4-dinitrobenzene (612.0 mg, 3.0 mmol) in DMF (1.5 ml) . The reaction solution
was stirred at room temperature for 45 min. This was followed by the addition of a
solution of 1-(3-aminopropyl) piperidine (477ml, 3.0 mmol) and DIEA (522.6 ml,
3.0 mmol) in DMF (2 ml). The resulting mixture was agitated at room temperature
overnight. Ethanol (60 ml), Pd/C (10%, 600 mg) and ammonium formate
(4.5 g, 71.4 mmol) were added to the solution. The solution was heated to reflux
for 4 h and then cooled to room temperature. The Pd/C was filtered out and the filtrate
was concentrated with a rotary evaporator. The residue was re-dissolved in ethanol
(40 ml), followed by addition of cyanogen bromide (321.3 mg, 3.6 mmol). The resulting
mixture was stirred at room temperature for 12 h. The precipitate was collected by
filtration and washed with ethanol, three times. The solid was dried in vacuum and
used for the next step without further purification. A portion of the solid (382.5 mg,
1.0 mmol) was weighed out and re-dissolved in NMP (1 ml), and was added the
solution of 4-(4-pyridinyl)benzoic acid (199.2 mg, 1.0 mmol), HBTU (379.3 mg,
1.0 mmol) and DIEA (348.4ml, 2.0 mmol) in NMP (3 ml). The resulting solution was
stirred at room temperature overnight. The precipitate was collected by filtration and
washed with ethanol followed by RP-HPLC purification. The fraction was collected and
lyophilized to give a yellow powder as the final product (Supplementary Figure S1).
The homogeneity of the compound was checked by analytical RP-HPLC. The purity
was determined to be 495% pure. The identity of the compound was confirmed by
matrix-assisted laser desorption/ionization-time of flight mass spectrometry, found:
564.28 Dalton (calculated: 564.31 Dalton for MHþ ).
Cell culture. RWPE1, LNCaP, Du145 and PC3 cells were obtained from
ATCC (Manassas, VA, USA) and maintained in RPMI-1640 medium containing
10% fetal bovine serum and 1% penicillin/streptomycin/glutamine.
Tissue microarray. The expression level of Btk in prostate cancer tissue was
examined using tissue microarray (PROS-006) from the UC Davis Pathology
department. The array was stained with anti-Btk antibody (Santa Cruz Inc., Santa
Cruz, CA, USA; sc-1107). The array contains 28 benign, 48 Gleason 6 (CaP 6),
46 Gleason 8 (CaP 8) prostate cancer samples. The expression level of Btk was
graded as no, low and high as illustrated in Figure 1a by an expert pathologist.
Btk ELISA. Btk levels in RWPE1, LNCaP, Du145 and PC3 cells were further
measured using the Btk ELISA assay kit (Abnova Inc., Littleton, CO, USA;
KA2617) according to the manufacturer’s protocol.
Reverse transcription and quantitative real-time PCR. Reverse
transcription and quantitative real-time PCR (qRT-PCR) were done as described
previously.30 Primer sequences used to amplify Btk fragments are listed as
follows: forward 50-GGTGGAGAGCACGAGATAAA-30; reverse 50-CCGAGTCATG
TGTTTGGAATAC-30 (IDTDNA Inc., Coralville, IA, USA). GAPDH was used as the
housekeeping gene.
Etk and Btk knockdown assay. Etk and Btk expression in PC3 and
RWPE1 cells was knocked down using siRNA. The Btk (Smartpool), Etk
(Smartpool) siRNA and non-targeted RNA were obtained from Dharmacon Inc.
(Lafayette, CO, USA). The siRNAs were transfected to cells according to the
manufacturer’s instruction. The expression levels of Btk and Etk were examined
using a western blot after 48 h. The growth rates were examined daily using an
MTT assay for 3 days. For comparison of SiBtk and LFM-A13, PC3 and Du145
cells were seeded at 5000 cells/well in 96-well plate overnight. Then, the cells
were transfected with SiBtk or treated with 50 mM LFM-A13, cell viability was
examined using an MTT assay at 72 h.
Kinase inhibition assay. Kinase inhibition was measured using TLC.
Briefly, purified kinases (20 nM), the corresponding substrate (500mM, TSFYGRH
for Etk, YIYGSFK for the other kinases) and CTN06 (0–10 mM) were incubated in
a kinase reaction (100 mM Hepes, pH 7.4, 10 mM MnCl2, 10 mM MgCl2, 1 mM
DTT) for 5 min, and the reaction was started by adding 5 mCi 33P-labaled ATP.
The reaction (10 ml) was incubated at room temperature for 1 h and was stopped
by adding 10ml H3PO4. The radioactivity of the peptide substrate was analyzed
using TLC as previously described.55
Molecular modeling. Molecular docking studies were performed to
determine the preferred binding site of CTN06 on the Btk structure. An energy
optimized structure of CTN06 was calculated using Merck Molecular Force Field
(MMFF) as implemented in Marvin Suite v 5.11 (http://www.chemaxon.com/
products/marvin). The crystal structure of Btk (PDB ID: 1K2P) that corresponds to
amino-acid positions 397–654 was used in our modeling studies. To define a
putative binding site for CTN06 on Btk protein structure, we first used a
blind docking approach, implemented on the SwissDock web service
(http://swissdock.vital-it.ch).56 Among the clusters generated by SwissDock, the
conformation with the lowest binding free energy was selected. To further confirm
the binding site predicted by blind docking, we used Autodock v4.2. Btk and
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CTN06 structures were prepared for docking using an Autodock Tools package.57
Partial atomic charges were assigned to CTN06 using the Gasteiger-Marsili
method, and, after the merging of non-polar hydrogens, rotatable bonds were
assigned using Autodock Tools. All the water molecules were removed from the
Btk structure, and the missing hydrogens and Kollman partial charges were added.
Further, non-polar hydrogens were merged to their corresponding carbons, and for
each atom the desolvation parameters were assigned. We used a grid size of
60 60 60 with grid spacing of 0.375 angstroms. The grid size was selected to
fit the whole ligand molecule. We used the Lamarckian Genetic Algorithm, called
Pseudo Solis-Wets Algorithm, to perform 256 independent docking runs with
default parameters in Autodock.58 Cluster analysis was performed on docked
results using an RMS tolerance of 2 angstroms.
To further understand the stability and dynamics of the ligand–kinase complex,
we performed a 20-ns molecular dynamics (MD) simulation, starting with the best-
docked structure predicted by Autodock-independent runs. These simulations were
performed using NAMD v 2.7b2.59 CHARMM27 force fields were used to calculate
the potentials of Btk, while CHARMM22 (as implemented in SwissParam, http://
swissparam.ch)60 force fields were used to calculate the potentials of CTN06. The
kinase–ligand complex was solvated in a water box with periodic boundary
conditions. Dimensions of the water box were selected to be at least 10 angstroms
larger than the solute in every direction. The whole system was neutralized with
0.15 M NaCl. An initial minimization step was performed for 6000 steps, followed by
20 ns of relaxation. Trajectories of these simulations were visualized using VMD v
1.9 (http://www.ks.uiuc.edu/Research/vmd/vmd-1.9/) and the interactions between
the kinase and the ligand were plotted using LigPlotþ v 1.4 and PyMol (http://
www.schrodinger.com/pymol/).
Western blotting. Western blotting was performed as described previously.61
Cells were grown in 100 mm dishes to about 50% confluence and treated with
vehicle (control) and CTN06 (0.5 and 2mM) for 12 h. Proteins were detected by
the following antibodies: b-actin (Sigma-Aldrich, A1978), Btk (Santa Cruz Inc.,
sc-1107), pBtk (pY233, Abcam, ab68217), Etk (Santa Cruz Inc., sc8874), pEtk
(pY40, 3211S), Src (2109), pSrc (pY416, 6943), PLCg2 (3872), pPLCg2 (pY759,
6943), Stat3 (12640), pStat3 (pY705, 4113), ERK (4696) and pERK (4695) were
obtained from Cell Signaling Inc. (Beverly, MA, USA). For pBtk and pEtk, cells
were pre-treated with 100mM pervanadate for 15 min before harvest.
MTT assay. Cells were seeded in 96-well plates and cultured overnight,
followed by treatment with 0.1% DMSO, as a vehicle control, and CTN06 at the
indicated concentrations for 72 h. Growth inhibition was measured using a 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Roche Diag-
nostic, Mannheim, Germany) according to the manufacturer’s protocol.
Flow cytometry. PC3 cells were treated with 0.1% DMSO (control) and
CTN06 at the indicated concentrations for 24 h. Cell-cycle arrest was determined
by the incorporation of propidium iodide (Sigma-Aldrich) into permeabilized cells.
Cells undergoing apoptosis were identified using an Annexin V-FITC kit (Abcam),
following the manufacturer’s instructions. The cells were analyzed using a Coulter
Epics XL flow cytometer (Beckman Coulter, Miami, FL, USA).
Microarray assay for miRNAs and cDNAs. PC3 cells were seeded at
106 cells/well in 6-well plate and treated with 0.5mM CTN06 for 18 h. Cells were
harvested and RNA was isolated using a trizol reagent (Ambion Inc., Grand Island,
NY, USA). Total RNA samples were submitted to the UC Davis Comprehensive
Cancer Center’s Genomics Shared Resource (GSR) for microarray profiling of
gene and miRNA expression and subsequent data analysis. The methods are
briefly described below.
Comprehensive gene expression profiling was performed with Affymetrix
GeneChip Human Genome U133 Plus 2.0 (HG-U133 Plus 2.0) (Affymetrix Inc.,
Santa Clara, CA, USA) arrays according to standard protocols described by the
manufacturer. Normalized probe set expression intensities were obtained using
robust multi-array average (RMA) for probe summarization and normalization of
background-adjusted and log-transformed perfect match probe intensity values.
The data set was filtered to retain only those probe sets having expression values
that exceeded the 5% lower cutoff threshold in at least one of the samples.
Comparison analysis was then performed to identify genes that were differentially
expressed between CTN06- and vehicle-treated cells. Criteria for the selection of
genes exhibiting significant expression changes included an average fold change of
Z2.0 between groups and P-values of r0.05. Global analysis of miRNA
expression was performed with Agilent Human miRNA Microarrays (Release 16.0)
(Agilent Technologies, Santa Clara, CA, USA) as per the manufacturer’s standard
protocols. Background-subtracted signal intensity values were log-transformed,
quantile-normalized and baseline transformed with GeneSpring GX12 software
(Agilent Technologies). The data set was then filtered for miRNAs exhibitingZ1.5-
fold differential expression in CTN06-treated cells relative to that of the vehicle-
treated controls. The miRNA profile was examined using GeneChip miRNA 2.0
Array (Affymetrix Inc.) and the gene expression profile was examined using cDNA
microarray (Affymetrix Inc.) by UC Davis Genome Center.
Autophagy assay. PC3 cells were stably transfected with GFP-LC3, as
previously described.30 Cells were grown in a 6-well plate to 50% confluence and
treated with 5 mM CTN06 for 24 h. Autophagy was visualized by GFP-LC3 ‘puncta’
and immunoblot of Endogenous LC3 isoforms under an Olympus BX61 motorized
reflected fluorescence microscope with FITC filter (excitation, 480 nm; emission,
535 nm) (Olympus America Inc., Melville, NY, USA) by using the SlideBook4.1
software (Intelligent Imaging Innovations, Denver, CO, USA).
PC3 cell ‘wound healing’ assay. PC3 cells were grown in 6-well plate to
60% confluency. Then wounds were made using a tip and treated with CTN06 (0
and 0.5mM). Cell migration (wound healing) was visualized under microscope at
the indicated times.
CTN06 as a chemo-sensitizer. Growth inhibition of CTN06 in combination
with 10mM CQ, 2 ng/ml DTX or 1mM AZD0530 (AZD), to PC3 human prostate
cancer cells was evaluated. Cells were seeded at 5000 cells/well in a 96-well plate
overnight and pre-treated with the corresponding co-treatments for 1 h, then treated
with 0.25mM CTN06. The cell viability was measured using an MTT assay after 72 h.
Inhibition of PC3 xenograft tumor growth by CTN06. Animal
experimental conditions were in accordance with the protocol approved by the
Institutional Animal Care and Use Committee at the University of California, Davis.
In all, 2 106 PC3 were injected subcutaneously to 5- to 6-week-old male nude
mice. Mice were randomly divided into two groups and treated with buffer only
(control) or 10 mg/kg/day CTN06 daily starting from 14 days after injection. The
size of tumors and body weight were measured once a week. After 42 days
treatment, mice were killed and tumors were harvested frozen in liquid nitrogen
and stored at  801C. Paraffin-embedded tumor tissues were sectioned to 5-mm
thickness and mounted on positively charged microscope slides, and 1 mM EDTA
(pH 8.0) was used for antigen retrieval. Immunohistochemistry was performed
using 1 : 200 dilution of Ki67 antibody (Cell Signaling Inc., 9027) and 1 : 50 dilution
of cleaved caspase 3 antibody (Cell Signaling Inc., 9664). Western blots were
performed using tumor lysates with LC3 antibody (Cell Signaling Inc., 4599).
Statistics. A one-way ANOVA was used in combination with a Tukey test for
pairwise comparison. P-values of o0.05 were considered as significant.
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